Surgeon Warns New Combination Weight Loss Drug Is More Powerful Than Ozempic on Lowest Dose

Two doctors have issued a stark warning against buying an unapproved combo weight-loss drug online after trial results showed participants shed roughly a fifth of their body weight even at the lowest dose tested.

The drug, Cagrisema, is manufactured by Danish pharmaceutical giant Novo Nordisk and remains in clinical trials with no regulatory approval anywhere in the world. A new study published in The Lancet Diabetes & Endocrinology tracked 309 adults without diabetes across Canada, France, Germany, the UK and the US for 68 weeks. Among those who completed the trial, participants on the 1mg dose lost 21% of their body weight, while those on the 1.7mg dose lost 20.7%. The placebo group lost just 2%.

Dr. Frank Agullo, a board-certified plastic surgeon in El Paso, Texas, cautioned that any Cagrisema available for purchase now lacks FDA approval and its safety profile remains completely unverified.

“The trial numbers are exciting, but a vial you bought online isn’t the drug from the trial. You don’t know the dose, you don’t know what else is in it, and you’re the one injecting it. Wait for the real thing and take it with a doctor who will watch what it does to your body,” he said.

Surgeon issues warning over new combo weight loss drug more powerful than Ozempic on 'lowest dose'

Dr. Andi Toufexis, a board-certified family medicine physician and founder of the nationwide obesity care practice SonaWell, echoed that patients purchasing from unverified sellers have “no reliable way” of determining what is actually in the vial, how much they are injecting, or whether the product is sterile. She drew a direct comparison to sourcing other prescription medications through unofficial channels.

“Now you have to figure out which pill makes sense for you, what dose to start with, whether it interacts with anything else you take, and whether it’s safe with your other health conditions,” she said.

Cagrisema combines semaglutide, the active ingredient in Ozempic and Wegovy, with cagrilintide, a compound that mimics amylin, a hormone that promotes satiety after eating. Toufexis explained that this dual mechanism attacks appetite through two distinct biological signals. In the 68-week trial, subjects on Cagrisema lost about 20% of their starting weight on average, compared with roughly 15% on semaglutide alone at the 2.4mg Wegovy dose, which she characterized as “a meaningful difference.” She noted that in a separate head-to-head trial, tirzepatide produced more weight loss, adding, “So how CagriSema stacks up depends on which drug you’re comparing it with.”

Agullo pointed out that the medication has no established long-term safety record. “While these are impressive results, it’s important to keep in mind that these results were from clinical trials and there is no long-term track record for this medication yet,” he said. Researchers have indicated that larger and more diverse trials are still needed to confirm the findings.

The most frequently reported side effects in the clinical trials were nausea, vomiting, constipation and diarrhea, mostly mild to moderate in severity, according to Agullo. He also raised concerns about gallbladder-related complications, pancreatitis and muscle loss. In his surgical practice, he has observed that rapid weight loss can trigger facial deflation leading to a “gaunt and aged appearance,” along with excess skin on the abdomen, arms and thighs.

Toufexis noted that approximately 8 in 10 participants in the REDEFINE 1 trial reported some form of digestive side effect, though most resolved over time. “If you’re vomiting repeatedly or can’t keep fluids down, that’s a reason to get medical advice promptly,” she said.

Novo Nordisk has been approached for comment.

Share this story